Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

IMUC signs exclusive licensing agreement with Targepeutics for acquisition of IL-13Ra2 receptor

ImmunoCellular Therapeutics, a clinical-stage biotechnology company focused on developing new immune-based products to treat cancer, today announced it has entered into an exclusive licensing agreement with Targepeutics, Inc. for ImmunoCellular's acquisition of Targepeutics' worldwide intellectual property rights surrounding the IL-13 receptor, alpha 2.

23 Jun 2010

Study investigates benefits of filtering blood to create safer approaches to transfusion therapy

Researchers at the University of Rochester Medical Center have discovered yet another reason to filter the foreign white cells from donor blood: The resulting blood product is associated with dramatically fewer cardiopulmonary complications for patients who received a transfusion.

23 Jun 2010

FDA grants Tolera's TOL101 orphan drug designation for treatment of T1DM

Tolera Therapeutics, Inc., was granted orphan drug status by the United States Food and Drug Administration (FDA) for TOL101 (anti-TCR murine monoclonal antibody, type IgM), for treatment of recent onset immune-mediated Type 1 diabetes mellitus (T1DM). Designation is granted for treatment of patients sixteen years of age and younger with immune-mediated T1DM and preserved pancreatic beta-cell function, commonly referred to as juvenile diabetes.

23 Jun 2010

Probactive Biotech, Dalat Nuclear Research Institute enter agreement to co-develop cancer drugs

Probactive Biotech, Inc., a Garden Grove, California-based corporation, has entered into an agreement with Dalat Nuclear Research Institute to co-develop a number of cancer drugs, utilizing combinations of antitumor antibodies and antitumor radioactive compounds. Antitumor antibodies have the ability to take antitumor compounds directly to the tumor sites within the body.

22 Jun 2010

SynCon DNA vaccine shows advantages in magnitude and breadth of immune responses in non-human primates

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the peer-reviewed journal Molecular Therapy has published a paper entitled "Comparative Analysis of Immune Responses Induced by Vaccination With SIV Antigens by Recombinant Ad5 Vector or Plasmid DNA in Rhesus Macaques." The paper, co-authored by researchers from Merck, University of Pennsylvania School of Medicine, and Inovio Pharmaceuticals, notes that significant advances in the design, formulation, and delivery of DNA plasmid-based vaccines have dramatically increased their ability to induce antigen-specific immune responses.

22 Jun 2010

Antibody treatment could significantly improve lives following spinal cord injury: Researchers

The United States Department of Defense Spinal Cord Injury Research Program has announced a grant of more than a million dollars U.S. to support research at the Robarts Research Institute at The University of Western Ontario (Western). The spinal cord injury research team of Gregory Dekaban, Arthur Brown, Lynne Weaver and Paula Foster, in collaboration with Brian Kwon of the University of British Columbia and Kyle Petersen of the U.S. Naval Medical Research Center, is working on a new therapy designed to limit the damage caused by inflammation immediately following spinal cord injury.

22 Jun 2010

UC Irvine researchers create "plastic antibodies"

UC Irvine researchers have developed the first "plastic antibodies" successfully employed in live organisms - stopping the spread of bee venom through the bloodstream of mice.

22 Jun 2010

OrbusNeich's Genous Bio-engineered R stent shows safety for percutaneous treatment of coronary artery stenosis

OrbusNeich today announced that six-month clinical follow-up data show the safety and efficacy of the combination of pre-dilatation with a paclitaxel drug-eluting balloon (Sequent Please®, B.Braun) followed by implantation of the company's Genous Bio-engineered R stent for the percutaneous treatment of coronary artery stenosis.

22 Jun 2010

FDA approves ARCHITECT HIV Ag/Ab Combo assay to aid in diagnosis of HIV-1/HIV-2 infection

The U.S. Food and Drug Administration today approved the first assay to detect both antigen and antibodies to Human Immunodeficiency Virus. This assay is approved for use as an aid in the diagnosis of HIV-1/HIV-2 infection in adults including pregnant women. It is also the first assay for use as an aid in the diagnosis of HIV-1/HIV-2 infection in children as young as two years old.

22 Jun 2010

FDA approves Abbott's ARCHITECT HIV Ag/Ab Combo assay

Every nine and a half minutes, someone in the United States is infected with HIV, and one out of every five of these individuals doesn't know it. To help stem the spread of this disease, the U.S. Food and Drug Administration (FDA) today approved an innovative new diagnostic tool, which will allow patients to be diagnosed earlier than ever before.

21 Jun 2010

NanoViricides' anti-Dengue drug candidates demonstrate potential against severe virus infection

NanoViricides, Inc. reports that its anti-Dengue drug candidates demonstrated significant protection in the initial animal survival studies of Dengue virus infection. The studies were performed in the laboratory of Dr. Eva Harris, Professor of Infectious Diseases at the University of California, Berkeley.

21 Jun 2010

Phase IIb EMBLEM study results of epratuzumab in patients with SLE presented at EULAR 2010

Immunomedics Inc. today announced that clinical trial results from the Phase IIb EMBLEM study of epratuzumab, a monoclonal antibody targeting CD22, in patients with moderate-severe systemic lupus erythematosus were presented at the 2010 annual Congress of the European League Against Rheumatism in Rome, Italy.

21 Jun 2010

Dyax signs partnership agreement with Sigma-Tau to develop and commercialize subcutaneous DX-88

Dyax Corp. and Defiante Farmaceutica S.A., a subsidiary of the pharmaceutical company Sigma-Tau SpA, announced today a strategic partnership to develop and commercialize subcutaneous DX-88 (ecallantide) for the treatment of hereditary angioedema and other therapeutic indications throughout Europe, North Africa, Middle East and Russia.

21 Jun 2010

Early-life exposure to PCBs diminishes immune response to diphtheria and tetanus vaccinations: Study

Children exposed to polychlorinated biphenyls early in life later had a diminished immune response to diphtheria and tetanus vaccinations, according to a study published online June 20 ahead of print in the peer-reviewed journal Environmental Health Perspectives. This result suggests that PCB exposure during the first years of life, a critical period in immune system development, could undermine the effectiveness of childhood vaccinations and possibly impair immune system responses to infection.

21 Jun 2010

AdnaGen signs option agreement to license specific antibodies to KellBenx

AdnaGen AG, a subsidiary of OncoVista Innovative Therapies, Inc., a high-growth global biotech company developing proprietary, leading-edge early detection and drug technologies to enable safe, targeted personal cancer treatments, today announced that it has entered into an option agreement to license specific antibodies to KellBenx Inc., a New York-based private biotech firm.

19 Jun 2010

Additional results from BLISS-52 Phase 3 trial of BENLYSTA for SLE to be presented at EULAR 2010

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced the presentation of additional results from BLISS-52, one of two pivotal Phase 3 trials of BENLYSTA (belimumab) in seropositive patients with systemic lupus erythematosus. The additional data will be presented in Rome at the 2010 Congress of the European League against Rheumatism on Saturday, June 19.

18 Jun 2010

Agilent launches 1260 Infinity bio-inert quaternary liquid chromatography system

Agilent Technologies Inc. today introduced the 1260 Infinity bio-inert quaternary liquid chromatography (LC) system designed to characterize and confirm large biomolecules, especially new biological entities (NBEs) and therapeutic monoclonal antibodies.

18 Jun 2010

Effects of SLE may differ based on patient's genealogical heritage: Study

The effects of Systemic Lupus Erythematosus may differ based on the individual patient's genealogical heritage, according to results of a new study presented today at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy. In particular, the study reinforced differences in SLE phenotype found between Northern and Southern European subpopulations.

18 Jun 2010

Roche implements risk mitigation plan in taspoglutide Phase III programme

Ipsen, a global biopharmaceutical group, today announced that its partner Roche today announced the implementation of a risk mitigation plan in the taspoglutide Phase III programme. Taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence, originating from Ipsen's research is developed by Roche. This compound is similar to the natural hormone GLP-1 which has a key role in blood sugar regulation.

18 Jun 2010

First clinical trial results of XOMA 052 in patients with uveitis of Behcet's disease presented at EULAR 2010

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced positive results from an open-label pilot study of XOMA 052 in patients with uveitis of Behcet's disease who were suffering from vision-threatening exacerbations despite maximal doses of immunosuppressive medicines.

17 Jun 2010

Antibody News and Research

Further Reading

IMUC signs exclusive licensing agreement with Targepeutics for acquisition of IL-13Ra2 receptor

Study investigates benefits of filtering blood to create safer approaches to transfusion therapy

FDA grants Tolera's TOL101 orphan drug designation for treatment of T1DM

Probactive Biotech, Dalat Nuclear Research Institute enter agreement to co-develop cancer drugs

SynCon DNA vaccine shows advantages in magnitude and breadth of immune responses in non-human primates

Antibody treatment could significantly improve lives following spinal cord injury: Researchers

UC Irvine researchers create "plastic antibodies"

OrbusNeich's Genous Bio-engineered R stent shows safety for percutaneous treatment of coronary artery stenosis

FDA approves ARCHITECT HIV Ag/Ab Combo assay to aid in diagnosis of HIV-1/HIV-2 infection

FDA approves Abbott's ARCHITECT HIV Ag/Ab Combo assay

NanoViricides' anti-Dengue drug candidates demonstrate potential against severe virus infection

Phase IIb EMBLEM study results of epratuzumab in patients with SLE presented at EULAR 2010

Dyax signs partnership agreement with Sigma-Tau to develop and commercialize subcutaneous DX-88

Early-life exposure to PCBs diminishes immune response to diphtheria and tetanus vaccinations: Study

AdnaGen signs option agreement to license specific antibodies to KellBenx

Additional results from BLISS-52 Phase 3 trial of BENLYSTA for SLE to be presented at EULAR 2010

Agilent launches 1260 Infinity bio-inert quaternary liquid chromatography system

Effects of SLE may differ based on patient's genealogical heritage: Study

Roche implements risk mitigation plan in taspoglutide Phase III programme

First clinical trial results of XOMA 052 in patients with uveitis of Behcet's disease presented at EULAR 2010

eBook: End-to-end solutions for bispecific antibody development eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo